TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03001596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemotherapy
Description: Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Esophagectomy
Description: After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Esophagectomy
Description: After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
Study: NCT02518360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic
Description: Body adjustment in three sessions (20 minutes/session).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auto Stretching
Description: The patients realize auto stretching in three sessions (20 minutes/session).
Study: NCT01978925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.~The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session.
Study: NCT04198090

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SGM Competency Training Program
Description: A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
Study: NCT04410380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic tablet provision with teaching
Description: Spanish-speaking parents are provided with an electronic tablet and taught how to use it to access health information for their children.
Study: NCT00736658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: Oral admin. of doses at 11 days through a 12 days period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral admin. of doses at 11 days through a 12 days period.
Study: NCT04258605

Intervention type: DEVICE
Intervention: ASHCOM Shoulder System
Description: Reverse Shoulder Arthroplasty
Study: NCT03564587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWAKE
Description: Behavioral intervention called Achieving Wellness After Kancer in Early Life (AWAKE) is focused on increasing hope in order to improve quality of life and health-promoting behaviors in survivors of young adult cancer. The AWAKE mobile app contains eight modules for participants to complete over 8 weeks with the ability to review prior modules. Participants receive a prompt on their mobile device weekly to complete each module and/or they will receive a text reminder. The app includes health education messaging, weekly homework assignments, the ability to track progress towards goals with self-monitoring and graphical depictions of progress, videos of inspirational materials, and a portal for interacting with their coach.
Study: NCT03320863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enso device
Description: An active Enso device that delivers neuromodulation therapy.
Study: NCT05609617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injection
Description: Intradermal injection on the face and neck/or décolleté by the NCTF135 HA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injection
Description: Intradermal injection on the face and neck/or décolleté by the NCTF135 HA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cream application
Description: Application of hydra filler cream on the face and neck/or décolleté

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cream application
Description: Application of hydra filler cream on the face and neck/or décolleté
Study: NCT04906070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HB-001
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT01340495

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: 45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
Study: NCT02589301

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT00629642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin Hydrochloride
Description: Oral, 15mg
Study: NCT03078491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eCGM (enhanced CGM)
Description: Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
Study: NCT04306042

Intervention type: DRUG
Intervention: Nivolumab or Pembrolizumab
Description: Nivolumab or Pembrolizumab
Study: NCT02153515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Your own ( autologous) finger prick of blood produced with a diabetic lancet
Study: NCT01982201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg
Study: NCT00629642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT02298569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-pronged program to improve early postpartum discharge
Description: Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.~Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration).
Study: NCT02767804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396 (ensartinib)
Description: oral ALK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crizotinib
Description: oral ALK inhibitor
Study: NCT04200274

Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: Online questionnaire via SoSciSurvey
Study: NCT00841542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate
Description: 10 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc®
Description: 10 mg Tablet
Study: NCT00835705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanic acid
Description: 400 mg-57 mg chewable tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin®
Description: 400 mg-57 mg chewable tablet
Study: NCT02699463

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continous Positive Airway Pressure
Description: CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Standard sleep hygiene counseling as per published guidelines
Study: NCT02332967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey predominant starter formula
Description: Milk powder product given to babies between 1 week and 4 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey predominant starter formula
Description: Milk powder product given to babies between 1 week and 4 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey predominant starter formula + 40% palmitic acid
Description: Milk powder product containing 40% of palmitic acid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey predominant starter formula + 50% palmitic acid
Description: Milk powder product containing 50% of palmitic acid
Study: NCT01934205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Single dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Single dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Single dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Single dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Single dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Single dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Multiple dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
Study: NCT03978156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 MG
Description: Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 MG
Description: Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microcrystalline cellulose
Description: Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microcrystalline cellulose
Description: Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
Study: NCT03081923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti-PD-L1 mono therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti-PD-L1 mono therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: anti-CTLA4 drug Tremelimumab mono therapy
Study: NCT01934205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Multiple dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Multiple dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Multiple dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Multiple dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 (Multiple dose)
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
Study: NCT01808651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Administered orally
Study: NCT02307994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75IU uFSH
Study: NCT01538459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
Study: NCT01876667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention (CPCRS) Group
Description: CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usual Care
Study: NCT01906372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic Hormone Gel
Description: H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
Study: NCT01982201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tums 500 mg and 750 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MINTOX 10 mL
Study: NCT01772979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Study: NCT03827876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar 0.005%-0.064% Topical Foam
Description: Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Study: NCT04330625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: REMD-477 will be administered as a subcutaneous injection for four weekly doses
Study: NCT03350711

Intervention type: OTHER
Intervention: Microbiota Enrichment Program (MEP)
Description: Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~* Health history and physical examination~* Urinalysis~* Urine or serum pregnancy test~* Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~* Electrocardiogram (EKG or ECG)~* Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database.
Study: NCT06081634

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhancing cognitive reserve
Description: Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions. For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: The group will only receive the pharmacoloical treatment according to the based guidelines.
Study: NCT04016740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Post-operative infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring
Description: Perioperative monitoring

Intervention type: DEVICE
Group type: OTHER
Intervention: EEG monitoring
Description: Perioperative monitoring
Study: NCT01867476

Intervention type: OTHER
Intervention: Automated Adherence Monitoring System
Study: NCT04014088

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hCPAP vs fCPAP
Description: The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hCPAP vs fCPAP
Description: The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
Study: NCT00720811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Description: 20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
Study: NCT02066038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
Study: NCT04383587

Intervention type: OTHER
Group type: OTHER
Intervention: Serologic testing
Description: COVID19 IgG antibody testing to be performed
Study: NCT02945618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurocryostimulation
Description: CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice
Description: The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
Study: NCT01403363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use of fentanyl patch that was halved
Description: A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
Study: NCT03644550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
Study: NCT00720811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxycillin
Description: amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days